Business Update5 Jun 2026, 08:13 pm
GlaxoSmithKline Pharmaceuticals Submits 2025-26 Annual Report
AI Summary
GlaxoSmithKline Pharmaceuticals Ltd has submitted its Annual Report for the financial year ended March 31, 2026, as per LODR Regulations. The report outlines the company's strategic focus on strengthening its core portfolio and expanding into specialty areas like adult immunisation, cancer care, and Hepatitis B treatment. GSK aims to provide high-quality preventive and curative medicines and vaccines to millions in India. The report includes financial statements, management discussion, and a 10-year performance summary, highlighting a commitment to innovation and accelerating impact in India's evolving healthcare landscape.
Key Highlights
- Annual Report for FY 2025-26 submitted.
- Focus on core portfolio and specialty areas.
- Strategic expansion into immunisation and cancer care.
- Commitment to quality medicines and vaccines.
- Advancing innovation and accelerating impact in healthcare.
Price Impact
More from GLAXO